PMID- 35747963
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 2212-3946 (Electronic)
IS  - 1574-888X (Linking)
VI  - 18
IP  - 3
DP  - 2023
TI  - Human Umbilical Cord Mesenchymal Stem Cells' Cultivation and Treatment of Liver 
      Diseases.
PG  - 286-298
LID - 10.2174/1574888X17666220623111406 [doi]
AB  - BACKGROUND: Over the past few years, mesenchymal stem cells (MSCs) have been 
      regarded as effective for treating various diseases. Among the types of MSCs, 
      human umbilical cord mesenchymal stem cells (hUC-MSCs) have been widely studied 
      because of their advantages in non-invasive damage to donors and the wide range 
      of sources. MAIN BODY: This article reviews three aspects of hUC-MSCs. Foremost 
      are the latest advances in the cultivation and preparation methods of hUC-MSCs. 
      Furthermore, the treatments mechanism of hUCMSCs in organ transplantation and 
      liver diseases. Finally, a summary of their use in clinical trials in liver 
      diseases. The first part of this paper emphasizes the differences between the 
      selection area and culture factors, including the separation method, long-term 
      culturing in vitro, medium composition, serum, and three-dimensional (3D) 
      skeleton system training, which could affect the characteristics of hUC-MSCs and 
      the treatment of diseases. The second section mainly stresses the mechanisms of 
      hUC-MSCs in the treatment of diseases, including immunoregulation and 
      transdifferentiation into hepatocyte-like cells. Many new technologies mark and 
      track cells in vivo and their safety. Briefly mention its role in the treatment 
      of other diseases and vaccine preparation. In the third part, to accelerate the 
      application of hUC-MSCs in the treatment of clinical diseases, it is necessary to 
      expand the sample size of clinical trials to ensure their safety in the human 
      body and determine the most effective infusion method and volume. CONCLUSION: 
      hUC-MSCs have a substantial potential to become a more effective treatment for 
      liver diseases. Clinical trials and mechanisms have laid the foundation for the 
      normalization of clinical hUC-MSCs delivery.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Zhu, Zihe
AU  - Zhu Z
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medicine, 
      Shanxi Medical University, Taiyuan, Shanxi Province, China.
FAU - Zhang, Qianqian
AU  - Zhang Q
AD  - Experimental Center of Science and Research, The First Clinical Hospital of 
      Shanxi Medical University, Taiyuan, Shanxi Province, China.
FAU - Liu, Lixin
AU  - Liu L
AD  - Experimental Center of Science and Research, The First Clinical Hospital of 
      Shanxi Medical University, Taiyuan, Shanxi Province, China.
FAU - Xu, Jun
AU  - Xu J
AD  - Hepatological surgery department, The First Clinical Hospital of Shanxi Medical 
      University, Taiyuan, Shanxi Province, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Stem Cell Res Ther
JT  - Current stem cell research & therapy
JID - 101272517
SB  - IM
MH  - Humans
MH  - Cell Differentiation
MH  - Umbilical Cord
MH  - *Mesenchymal Stem Cells
MH  - Hepatocytes
MH  - *Liver Diseases/therapy
MH  - *Mesenchymal Stem Cell Transplantation
OTO - NOTNLM
OT  - 3D scaffold culture system
OT  - Umbilical cord mesenchymal stem cells
OT  - immunoregulation
OT  - liver diseases
OT  - mechanism
OT  - treatment
EDAT- 2022/06/25 06:00
MHDA- 2023/05/22 06:42
CRDT- 2022/06/24 02:43
PHST- 2021/11/15 00:00 [received]
PHST- 2022/02/28 00:00 [revised]
PHST- 2022/03/08 00:00 [accepted]
PHST- 2023/05/22 06:42 [medline]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/24 02:43 [entrez]
AID - CSCR-EPUB-124734 [pii]
AID - 10.2174/1574888X17666220623111406 [doi]
PST - ppublish
SO  - Curr Stem Cell Res Ther. 2023;18(3):286-298. doi: 
      10.2174/1574888X17666220623111406.